Lenalidomide delays progression of smouldering multiple myeloma
Treatment, rather than observation, is now appropriate, say researchers
Early treatment with lenalidomide significantly delays the progression of smouldering multiple myeloma to symptomatic disease, according to the results of a randomised trial.
Dr Sagar Lonial, of Emory University School of Medicine in Atlanta, and colleagues compared the efficacy of single-agent lenalidomide with observation only, the current standard of care for the precursor disease, in 182 patients with intermediate- or high-risk smouldering multiple myeloma.
